KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$5.79 USD
-0.01 (-0.17%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.84 +0.05 (0.86%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KALA 5.79 -0.01(-0.17%)
Will KALA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KALA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KALA
KALA BIO (KALA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
KALA: What are Zacks experts saying now?
Zacks Private Portfolio Services
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
VYNE Gains on Preclinical Data for IPF Candidate
Other News for KALA
Oppenheimer 'encouraged' by Kala Pharmaceuticals trial progress
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Buy Rating for Kala Pharmaceuticals Amidst Promising Clinical Trials and Strong Financials
Kala Pharmaceuticals price target lowered by $3 at H.C. Wainwright, here's why
KALA Stock Earnings: Kala Bio Beats EPS for Q2 2024